Drug Type Small molecule drug |
Synonyms Peretinoin (JAN) + [2] |
Target |
Mechanism RARs agonists(Retinoic acid receptors agonists), RXRs agonists(Retinoid X receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationSpecial Review Project (CN), Orphan Drug (EU) |
Molecular FormulaC20H30O2 |
InChIKeyUUBHZHZSIKRVIV-KCXSXWJSSA-N |
CAS Registry81485-25-8 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hepatocellular Carcinoma | Phase 3 | - | - | |
Hepatocellular Carcinoma | Phase 3 | - | - |
Phase 3 | 616 | (NIK-333(Peretinoin)) | odyihbzhio(ucsifswhww) = cskkocmqkm brgqnutbvp (fvwsgbeycl, ukvobjjpgg - wlmzwvqcvz) View more | - | 02 Dec 2020 | ||
Placebo (Placebo) | odyihbzhio(ucsifswhww) = vtwfyyypln brgqnutbvp (fvwsgbeycl, icwerybbqh - vyvpxnxsdm) View more | ||||||
Phase 2/3 | 401 | - | - | 01 Feb 2011 | |||